Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Microlyvaq
- Development stage
- Phase 1
- Lead developer
- Biogenea Pharmaceuticals
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Subcutaneous, Intradermal
01
Overview
Microlyvaq is a personalized, multi-epitope cancer vaccine developed by Biogenea Pharmaceuticals Ltd for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC). The vaccine is designed using a proprietary AI-driven platform that incorporates quantum mechanics/molecular mechanics (AI-QMMM) to identify and select patient-specific neoantigens derived from whole exome and RNA sequencing of the individual's tumor. These private neoantigens are combined with a standardized panel of tumor-associated antigens (TAAs), including NY-ESO-1, SOX2, MAGE-A4, p53, and BRAF, to create a multi-targeted immunotherapy. Microlyvaq aims to stimulate a robust, polyfunctional immune response by recruiting both CD8+ cytotoxic T cells and CD4+ Th1 helper T cells. In clinical settings, it is evaluated as part of a combination regimen with pembrolizumab and platinum-based chemotherapy to enhance anti-tumor efficacy and overcome immune evasion mechanisms.
- Brand names
- Microlyvaq
- Other names
- Microlyvaq vaccinePersonalized Multi-Epitope Immunotherapeutic
02
Targets
Human leukocyte antigen class I and class II moleculeNY-ESO-1 (New york esophageal squamous cell carcinoma 1)TP53 (Cellular Tumor Antigen p53 R175H)MAGEA4 (Melanoma-associated antigen A4)BRAF (B-Raf proto-oncogene, serine/threonine kinase)SOX2 (SRY-box transcription factor 2)pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on Microlyvaq.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Microlyvaq.